Imatinib Ratiopharm (Imatinib)

Imatinib works by binding to the ATP‑binding pocket of BCR‑ABL, KIT and PDGFR tyrosine kinases. This blocks phosphorylation of downstream signaling proteins, halting the proliferative signals that drive malignant cell growth and ultimately leading to cancer cell death.

The dose of Imatinib Ratiopharm is individualized by the prescribing physician based on the specific indication, disease stage, patient weight, and tolerability. The medication is supplied as oral tablets, and the prescriber determines the strength and dosing schedule appropriate for each patient.

Safety data for Imatinib Ratiopharm in pregnancy and lactation are limited. It should be used only if the potential benefit to the mother outweighs the possible risk to the fetus or infant, and the decision should be made in consultation with a qualified healthcare professional.

To order Imatinib Ratiopharm, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Imatinib was the first BCR‑ABL inhibitor and is generally well‑tolerated, but newer agents such as dasatinib and nilotinib have higher potency and may be preferred in cases of resistance or intolerance. Choice of therapy depends on disease characteristics, prior treatment history, side‑effect profile, and physician judgment.

Imatinib Ratiopharm tablets should be stored at temperatures below 25 °C, in the original container, protected from moisture and direct sunlight. Keep the product out of reach of children and do not use if the packaging is damaged.

Imatinib Ratiopharm is taken orally, usually with a glass of water. It can be taken with or without food, but patients should follow the specific instructions provided by their prescriber to maintain consistent absorption.

Serious risks include severe neutropenia, hepatotoxicity, and cardiac failure. Patients should be monitored regularly for blood‑cell counts, liver enzyme levels, and cardiac function, and any signs of infection, jaundice, or heart problems should be reported to a healthcare professional immediately.

Imatinib Ratiopharm should be avoided in patients with known hypersensitivity to imatinib or any of its excipients. Caution is also advised for individuals with pre‑existing severe liver disease, uncontrolled cardiac conditions, or those taking strong CYP3A4 inducers or inhibitors without appropriate medical supervision.